Production (Stage)
ABVC BioPharma, Inc.
ABVC
$1.15
-$0.06-4.96%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 510.70K | 511.90K | 650.70K | 286.60K | 175.60K |
| Total Other Revenue | -2.30K | -2.30K | -141.00K | -134.40K | -134.40K |
| Total Revenue | 508.40K | 509.60K | 509.80K | 136.40K | 25.40K |
| Cost of Revenue | 500.00 | 800.00 | 140.00K | 169.30K | 242.10K |
| Gross Profit | 508.00K | 508.90K | 369.90K | -32.80K | -216.70K |
| SG&A Expenses | 2.32M | 4.43M | 4.43M | 6.13M | 6.69M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 28.60K | 28.60K | -18.10K | 9.60K | 9.60K |
| Total Operating Expenses | 2.49M | 4.64M | 4.77M | 6.63M | 7.73M |
| Operating Income | -1.98M | -4.13M | -4.26M | -6.49M | -7.71M |
| Income Before Tax | -2.33M | -4.32M | -4.97M | -8.21M | -9.06M |
| Income Tax Expenses | -110.50K | -110.50K | 64.80K | 63.40K | 256.00K |
| Earnings from Continuing Operations | -2.22 | -4.21 | -5.04 | -8.27 | -9.31 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 410.20K | 401.60K | 618.20K | 721.10K | 512.80K |
| Net Income | -1.81M | -3.80M | -4.42M | -7.55M | -8.80M |
| EBIT | -1.98M | -4.13M | -4.26M | -6.49M | -7.71M |
| EBITDA | -1.94M | -4.10M | -4.23M | -6.46M | -7.69M |
| EPS Basic | -0.14 | -0.38 | -0.45 | -1.26 | -1.85 |
| Normalized Basic EPS | -0.08 | -0.23 | -0.22 | -0.72 | -1.07 |
| EPS Diluted | -0.15 | -0.38 | -0.46 | -1.26 | -1.85 |
| Normalized Diluted EPS | -0.08 | -0.23 | -0.22 | -0.72 | -1.07 |
| Average Basic Shares Outstanding | 51.90M | 46.67M | 40.14M | 31.79M | 23.78M |
| Average Diluted Shares Outstanding | 51.90M | 46.67M | 40.14M | 31.79M | 23.78M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |